0 94

Cited 5 times in

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.

Authors
 Ji-Won Kim  ;  Byung-Su Kim  ;  Soo-Mee Bang  ;  Inho Kim  ;  Dong Hwan Kim  ;  Won Seog Kim  ;  Deok-Hwan Yang  ;  Je-Jung Lee  ;  Je-Hwan Lee  ;  Jin Seok Kim  ;  Sang-Kyun Sohn  ;  Ho-Young Yhim  ;  Jae-Yong Kwak  ;  Sung-Soo Yoon  ;  Jong Seok Lee  ;  Seonyang Park  ;  Byoung Kook Kim 
Citation
 ANNALS OF HEMATOLOGY, Vol.90(12) : 1409-1418, 2011 
Journal Title
 ANNALS OF HEMATOLOGY 
ISSN
 0939-5555 
Issue Date
2011
MeSH
Adolescent ; Adult ; Disease Progression* ; Female ; Humans ; Korea ; Lymphoma, Non-Hodgkin/physiopathology* ; Lymphoma, Non-Hodgkin/prevention & control* ; Lymphoma, Non-Hodgkin/therapy* ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Stem Cell Transplantation* ; Survival Rate ; Transplantation Conditioning ; Transplantation, Homologous*/adverse effects ; Treatment Outcome ; Young Adult
Keywords
Non-Hodgkin lymphoma ; Stem cell transplantation ; Donor lymphocyte infusion ; Performance status ; Albumin
Abstract
There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p=0.022), performance status (p<0.001), and baseline serum albumin level (p=0.010) were significant risk factors for OS. Performance status (p=0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT
Full Text
https://link.springer.com/article/10.1007%2Fs00277-011-1227-y
DOI
10.1007/s00277-011-1227-y
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165800
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse